Evaluation of a topical steroid antibiotic combination (halcinonide-neomycin-amphotericin) in the treatment of cutaneous candidiasis and inflammatory dermatoses.
Halcinonide-neomycin-amphotericin (HNA) cream was evaluated in the treatment of cutaneous candidiasis and inflammatory dermatoses. The anti-candidal properties of HNA were assessed in a parallel comparison with iodochlorhydroxyquin-hydrocortisone (I-HC) as the control drug. The overall therapeutic response with HNA was excellent in 38 (95%) of 40 patients as compared to 17 (43%) of 40 treated with I-HC. In 50 patients treated for psoriasis, eczematous dermatitis, or neurodermatitis, HNA was evaluated in a paired comparison with hydrocortisone (HC). The overall therapeutic response with HNA was excellent in 36 (72%) patients as compared to 18 (36%) with HC. There were no adverse reactions with HNA or the control drugs.
D000287:Administration, Topical; D000293:Adolescent; D000328:Adult; D000368:Aged; D000666:Amphotericin B / Q000627:therapeutic use*; D000893:Anti-Inflammatory Agents / Q000627:therapeutic use; D002179:Candidiasis, Cutaneous / Q000188:drug therapy*; D002648:Child; D002986:Clinical Trials as Topic; D007464:Clioquinol / Q000627:therapeutic use; D003872:Dermatitis / Q000188:drug therapy*; D004338:Drug Combinations; D005260:Female; D006206:Halcinonide / Q000627:therapeutic use*; D006801:Humans; D006854:Hydrocortisone; D008297:Male; D008875:Middle Aged; D009355:Neomycin / Q000627:therapeutic use*; D011282:Pregnenediones / Q000627:therapeutic use*; D013997:Time Factors
D000893:Anti-Inflammatory Agents; D004338:Drug Combinations; D011282:Pregnenediones; D007464:Clioquinol; D000666:Amphotericin B; D009355:Neomycin; D006206:Halcinonide; D006854:Hydrocortisone